Company news

Neurocrine Biosciences, Inc. news in 2020

Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

November 8, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

October 5, 2020

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

September 13, 2020

Neurocrine Biosciences Reports Second Quarter 2020 Financial Results

August 2, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

July 12, 2020

Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

June 15, 2020

Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy

May 10, 2020

Neurocrine Biosciences Reports First Quarter 2020 Financial Results

May 5, 2020

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

April 26, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results

April 14, 2020

Neurocrine Biosciences Provides COVID-19 Business Update

April 2, 2020

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

February 3, 2020

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

February 2, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

January 19, 2020

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

January 11, 2020

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

January 9, 2020

Calls in 2020

Decks in 2020